ArticleScientific reports2026
Suppression of LTBP1 enhances the sensitivity of bladder cancer to cisplatin.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cisplatin-based chemotherapy is the primary treatment for advanced bladder cancer; however, numerous patients experience treatment failure because of chemoresistance. Therefore, it is crucial to identify drivers of chemoresistance and determine strategies to counteract them to improve prognosis in bladder cancer patients. This study performed proteomics analysis of clinical samples of cisplatin-naïve and resistant bladder cancer tissues. Furthermore, the GEO and TCGA datasets were integrated, which revealed latent transforming growth factor β binding protein 1 (LTBP1) as a potential gene associated with chemoresistance in bladder cancer. LTBP1 expression was correlated with clinical stage and patient survival. LTBP1 knockdown in bladder cancer cells inhibited proliferation, migration, invasion, and chemoresistance via TGF-β-mediated epithelial-mesenchymal transition. Subcutaneous tumor and lung metastasis mouse models revealed that LTBP1 inhibition combined with cisplatin treatment significantly inhibited tumor growth and metastasis. Higher LTBP1 expression is associated with a worse prognosis and advanced stage in bladder cancer patients. In conclusion, this study revealed that LTBP1 may be a potential target for alleviating chemoresistance in bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.